Generic Product News (August 2015)

Pharmacy TimesAugust 2015 Pain Awareness
Volume 81
Issue 8

Read about the new generic products featured in August.

Marketed by: Teva Pharmaceuticals

Compare to: Aggrenox (Boehringer Ingelheim)

Indication: Teva Pharmaceuticals has launched Aspirin and Extended-Release Dipyridamole Capsules, a generic equivalent to Boehringer Ingelheim’s Aggrenox. The capsules are an antiplatelet agent indicated to lower the risk of stroke in patients who have had a transient ischemic attack (mini-stroke) or stroke due to a blood clot. The product is contraindicated in patients with known sensitivities to either ingredient component, and it is not interchangeable with the individual components of aspirin and dipyridamole tablets.

Dosage Form: Capsules: 25 mg

For More Information:

Almotriptan Malate TabletsMarketed by: Teva Pharmaceuticals

Compare to: Axert (Janssen Pharmaceuticals)

Indication: Teva Pharmaceuticals has launched Almotriptan Malate Tablets, an anti-migraine agent that is the generic equivalent of Janssen Pharmaceuticals’ Axert. The drug is indicated for adults and adolescents aged 12 to 17 years, although efficacy has not been established in treating migraine symptoms in adolescents. The tablets are contraindicated in patients with ischemic heart disease (IHD) or patients who have symptoms consistent with IHD. The drug should only be used when a clear diagnosis of migraine has been established.

Dosage Form: Tablets: 6.5 mg and 12.5 mg

For More Information:

Glatiramer Acetate (Glatopa)

Marketed by: Sandoz

Compare to: Copaxone (Teva)

Indication: Sandoz has announced the launch of once-daily Glatiramer Acetate, the first generic competitor to Copaxone (Teva), to treat relapsing forms of multiple sclerosis (MS) in patients who have experienced a first clinical episode and have MRI features consistent with MS. The drug is contraindicated in patients with established hypersensitivity to glatiramer acetate or mannitol. Adverse events, including flushing, chest pain, palpitations, and anxiety, had their onset several months after treatment initiation and occurred in about 16% of patients.

Dosage Form: Injection: 20 mg/mL

For More Information:

Bexarotene Capsules

Marketed by: Mylan N.V.

Compare to: Targretin (Valeant)

Indication: Mylan N.V. has announced the launch of Bexarotene Capsules, the generic equivalent of Valeant’s Targretin. The drug is indicated to treat cutaneous manifestations of cutaneous t-cell lymphoma in patients who were refractory to at least 1 prior systemic therapy. Common adverse effects associated with bexarotene include headache, weakness, tiredness, and increased sensitivity to cold. The drug is a member of the retinoid class of drugs associated with birth defects.

Dosage Form: Tablets: 75 mg

For More Information:

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.